Neurocrine’s Strategic Partnership with Takeda: A Catalyst for Growth and Financial Upside
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...
Stifel maintains Neurocrine Bio stock target, positive on Takeda deal
Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...
The Pharma Letter1d
Neurocrine revamps osavampator deal with Takeda
USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...
BioSpace1d
Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...
Neurocrine announces amendment to collaboration with Takeda
Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...
Pharmabiz1d
Neurocrine Biosciences and Takeda amend strategic collaboration to develop and commercialize osavampator
Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...
Neurocrine Biosciences director sells shares worth $21.8 million
Kevin Charles Gorman, a director at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Gorman sold 146,105 ...